Global Pharma and Biotech Summit
Video on demand now available!
The world of life sciences is in a period of relentless disruption. Advances in technology are transforming research and development. Innovative treatments are reshaping healthcare as we know it. Meanwhile, companies face the challenge of bringing products to market in an unsettled regulatory environment.
The Global Pharma and Biotech Summit is the essential annual event for you to stay on top of the latest trends in life sciences. Industry leaders and experts will discuss what’s new in areas such as drug discovery, clinical trials, market access and patient engagement.
A huge thank you to all those who attended in-person and online, to all of our incredible speakers and valued sponsors. We hope to see you all again next year in November 2025.
.jpg)
Why attend?
Understand
the technology and innovation behind new treatments with the power to transform healthcare.
Connect
with industry leaders responsible for the big decisions in areas such as investment, innovation and market access.
Discover
new ideas to support business transformation and maximise return on investment.
Free Industry Reports
Obesity Drugs: Market Dynamics and Growth Potential
The era-defining success of GLP-1 agonists as treatments for obesity and the explosion in demand for them is fueling innovation and investment in the field. Get a taste of what's being covered at this year's Global Pharma and Biotech Summit by downloading our industry report on 'Obesity Drugs: Market Dynamics and Growth Potential'.
"This was my first time attending a FT Live Event and I believe it was really well done. I wish it had been a two day event - simply because it allows for more sharing of information and networking."
- Head of Life Sciences, Novo Nordisk
Supporting Partners
Speaking Opportunities
Ciaran Larkin
ciaran.larkin@ft.com
Sponsorship Opportunities
Holly Watson-Steward
holly.watson-steward@ft.com
Delegate Services
Hauwra Sharif
hauwra.sharif@ft.com
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
